Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment is still a challenge in lower-middle income countries. The availability of the biosimilar trastuzumab has improved access by lowering the costs. We r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ecancermedicalscience
Main Authors: Joel, Anjana, Georgy, Josh Thomas, Thumaty, Divya Bala, John, Ajoy Oommen, Chacko, Raju Titus, Rebekah, Grace, Sigamani, Elanthenral, Chandramohan, Jagan, Manipadam, Marie Therese, Cherian, Anish Jacob, Abraham, Deepak Thomas, Jacob, Paul Mazhuvanchary, Sebastian, Patricia, Backianathan, Selvamani, Singh, Ashish
Formato: Artigo
Idioma:Inglês
Publicado: Cancer Intelligence 2021
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057782/
https://ncbi.nlm.nih.gov/pubmed/33912232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1207
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares